Syn2Bio

Syn2Bio S.A. Board Member's Close Associate Acquires Company Shares

On April 20, 2026, Syn2Bio S.A. announced a transaction involving the acquisition of 2,300 company shares by Mr. Maciej Zarębiński, a close associate of Ms. Sawa Zarębińska, a member of the Supervisory Board. The shares were purchased at a price of 34 PLN per share on April 16, 2026, through the Warsaw Stock Exchange (XWAR). The transaction was disclosed in compliance with Article 19(1) of the MAR Regulation, and the full notification is available in the company's official report.

This development highlights the confidence of individuals closely associated with Syn2Bio's leadership in the company's future prospects, particularly as it advances its innovative cardiotracer radiopharmaceutical through phase-three clinical trials and continues its efforts in pharmaceutical research and commercialization.

Insider Transaction Reported at Syn2Bio S.A. Involving Board Member's Close Associate

On April 20, 2026, Syn2Bio S.A. announced a transaction involving the acquisition of company shares by Ms. Zuzanna Zarębińska, a close associate of Ms. Sawa Zarębińska, a member of the Supervisory Board. The transaction, conducted on April 16, 2026, involved the purchase of 30 shares at a price of 33.9 PLN per share on the Warsaw Stock Exchange (XWAR). The notification was made in compliance with Article 19(1) of the MAR Regulation, and the full details are available in the attached report.

This development highlights the ongoing confidence in Syn2Bio S.A.'s strategic direction and its innovative projects, including the advanced phase-three clinical trials of its cardiotracer radiopharmaceutical for heart disease diagnosis.

Syn2Bio S.A. Acquires Founding Shares for Strategic Realignment

On April 22, 2026, Syn2Bio S.A., headquartered in Warsaw, finalized an agreement to acquire 200,000 Series A bearer shares, representing 2.29% of its share capital. The shares, valued at a nominal price of 0.50 PLN each, were purchased for a total of 100,000 PLN from shareholders Anna Szymańska and Cezary Kozanecki. This acquisition follows a preliminary agreement signed on February 18, 2026, and detailed in the company's prospectus approved by the Polish Financial Supervision Authority on March 12, 2026.

The acquired shares, originally technical founding shares, were issued to facilitate the division of Synektik S.A. and align the shareholder structure of Syn2Bio S.A. with that of Synektik S.A. The company plans to cancel these shares during the next general shareholders' meeting, ensuring a streamlined ownership structure.

Relevance: This strategic move underscores Syn2Bio S.A.'s commitment to optimizing its corporate structure as it advances its flagship cardiotracer radiopharmaceutical project, currently in phase-three clinical trials.

Syn2Bio S.A. Announces Extraordinary General Meeting to Address Key Corporate Decisions

Syn2Bio S.A., a leading Polish company specializing in innovative radiopharmaceuticals for heart disease diagnosis, has announced the convening of an Extraordinary General Meeting (EGM) scheduled for May 19, 2026, at its headquarters in Warsaw. The meeting will address critical corporate matters, including the voluntary redemption of 200,000 company shares, a reduction in share capital, and amendments to the company's statute. Additionally, the agenda includes the adoption of a new remuneration policy and the approval of the updated regulations for the Supervisory Board.

The share capital reduction aims to align the company's capital structure with its post-reorganization shareholder composition following the division of Synektik S.A. The new remuneration policy seeks to enhance corporate governance and align executive compensation with long-term business goals. The meeting will also finalize the rules governing the Supervisory Board, ensuring compliance with corporate governance standards.

Relevance to Syn2Bio S.A.: These decisions are pivotal for Syn2Bio S.A. as they directly impact its organizational structure and governance, which are crucial for the successful commercialization of its cardiotracer project currently in Phase III clinical trials.